BOULDER, Colo.--(BUSINESS WIRE)--MiRagen Therapeutics, Inc., a biopharmaceutical company developing innovative microRNA (miRNA)-based therapeutics primarily for the treatment of patients who suffer from cardiovascular and muscle disease, announced today that Dr. Arthur A. Levin has joined its executive team as Executive Vice President of Research and Development. In this role, Dr. Levin will be responsible for advancing miRagen’s current product candidates into development and for leading discovery research efforts aimed at expanding the company’s pipeline.
